ストックスクリーナーアプリを入手
23.70
12.11%
2.56
アフターアワーズ：
23.70
Anaptysbio Inc (ANAB) 最新ニュース
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha
AnaptysBio (NASDAQ:ANAB) Trading Up 9.1%What's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4.5%Should You Sell? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC - MarketBeat
TD Cowen reiterates Buy rating on AnaptysBio stock following updated trial data - Investing.com Canada
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
AnaptysBio (ANAB) Shares Drop Amid Trial Data Missteps - GuruFocus
HC Wainwright & Co. Upgrades AnaptysBio (LSE:0HFQ) - Nasdaq
J&J hurts AnaptysBio with anti-inflammatory data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumato - GuruFocus
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - Benzinga
AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumatoid Arthritis | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's Why - MarketBeat
H.C. Wainwright upgrades AnaptysBio stock on positive trial data By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Upgraded to Buy at HC Wainwright - MarketBeat
Anaptys stock gains on arthritis drug data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial - Insider Monkey
HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq
AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New Target Price | ANAB Stock News - GuruFocus
HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target - marketscreener.com
Stifel Reiterates Buy Rating on AnaptysBio (ANAB) - StreetInsider
AnaptysBio (ANAB) Gets Boost from Positive Phase 2 Trial Data | ANAB Stock News - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com South Africa
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India
Transcript : AnaptysBio, Inc.Special Call - marketscreener.com
AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks
AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com
AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | ANAB Stock News - GuruFocus
Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $199,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Deutsche Bank AG Purchases 6,113 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up After Analyst Upgrade - MarketBeat
Voloridge Investment Management LLC Sells 85,708 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Investments LP Buys 140,457 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush - MarketBeat
Trading (ANAB) With Integrated Risk Controls - news.stocktradersdaily.com
AnaptysBio (NASDAQ:ANAB) Trading Up 6.6%What's Next? - MarketBeat
Woodline Partners LP Purchases 25,094 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Advisers LP Has $3.88 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at Guggenheim - MarketBeat
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim - Defense World
Northern Trust Corp Grows Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $90.00 at Guggenheim - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade - Defense World
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock - Benzinga
AnaptysBio (ANAB) Maintains Buy Rating with Raised Price Target | ANAB Stock News - GuruFocus
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - Benzinga
Guggenheim raises AnaptysBio stock target to $90, maintains Buy By Investing.com - Investing.com India
Guggenheim raises AnaptysBio stock target to $90, maintains Buy - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Position Lessened by BNP Paribas Financial Markets - Defense World
AnaptysBio (ANAB) Sees Price Target Uplift Amid Positive Developments | ANAB Stock News - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilim - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 | ANAB Stock News - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - The Manila Times
AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data on Rosnilimab for Rheumatoid Arthritis - Nasdaq
Anaptys to Announce Updated Data from Phase 2b Trial of - GlobeNewswire
New PD-1 Drug Trial Data: Rosnilimab Shows Promise for Rheumatoid Arthritis TreatmentKey Results Coming - Stock Titan
0.00%
2.33%
大文字化:
|
ボリューム (24 時間):